



dorsaVi adds to growing patent portfolio with dorsaVi's 'measuring reaction forces' patent to be granted in the important US market

Key highlights:

- **New 'measuring reaction forces' patent to be granted in the US is related to the dorsaVi running product that is currently being used by over 400 customers globally**
- **The patent aims to protect and support dorsaVi's technology and commercial strategy within the running market, with the US being the largest running market sector**
- **dorsaVi's growing patent portfolio highlights the cutting-edge innovation that is at the centre of dorsaVi's wearable motion analysis technology**
- **Strong IP position is a key differentiator for dorsaVi in both clinical and workplace markets**
- **A total of seven IP families are held by the Company with 16 patents granted across eight countries**

Melbourne, Australia, 18 November 2019; dorsaVi (ASX: DVL) is pleased to announce the strengthening of its intellectual property position with the granting of the 'measuring reaction forces' patent in the US.

This patent has been previously granted in Australia (2013302207) and in China (ZL 201380042073.0). The new patent not only protects dorsaVi's technologies but allows the Company to continue to evolve its products and maintain its global leadership position in medical grade wearables.

The US Patent & Trademark Office has issued a Notice of Allowance for dorsaVi's patent application, *Apparatus and method for measuring reaction forces*. This patent application protects the apparatus (the sensors) and also the method (the algorithms) that allow dorsaVi's sensor technology to determine the reaction force of the limb contacting the ground or surface that the person is walking or running on. This is an important component when assessing whether certain movements are associated with a higher risk of causing or contributing to an injury. This data is relevant for dorsaVi customers in the workplace, sports and clinical markets. The patent has a 20-year term and will expire on 24 July 2033.

- ENDS -

For more information about dorsaVi or to arrange an interview, please contact:

MEDIA
Megan Connell
dorsaVi
0416 116 526
mconnell@dorsavi.com

About *dorsaVi*

dorsaVi (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in elite sports, occupational health and safety and clinical applications. *dorsaVi* believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- **Clinical:** *dorsaVi* is transforming the management of patients with its clinical solutions - ViMove, ViMove2 and Professional Suite – which provide objective assessment, monitoring outside the clinic and immediate biofeedback. *dorsaVi* is currently used by medical and physiotherapy practices globally.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used in the US by the National Basketball Association (NBA), the Major Soccer League (MLS) and the National Football League (NFL), by the AFL and NRL clubs, Cricket Australia, and the Australian Institute of Sport (AIS) in Australia, and by Barclays Premier League (EPL) clubs, England and Wales Cricket Board and the Board of Control for Cricket in India as well as various Olympic teams and athletes internationally.
- **OHS:** *dorsaVi* enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment or methods based on objective evidence. *dorsaVi* has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor), Crown and BHP Billiton.

Further information is available at www.dorsavi.com.